Leadership

Armenian American Health Professionals Organization

1 month ago

Read the Armenian Mirror-Spectator article! conta.cc/3T4yi4r ... See MoreSee Less

Late But Not Too Late: Charity Benefit on Oct. 16

conta.cc

Read the Armenian Mirror-Spectator article What's Happening What's Next October 14, 2022 Click an Icon to Connect with AAHPO Visit our website AAHPO Program Named for Dr. Raffy Hovanessian Aims

View on Facebook

Armenian American Health Professionals Organization

2 months ago

Please support the AAHPO, Dr. Raffy Hovanessian Medical Education Program! ... See MoreSee Less

Video

View on Facebook

Armenian American Health Professionals Organization

2 months ago

Please join us October 16 or donate: aahpo.org/donate/ Event to benefit the AAHPO, Dr. Raffy Hovanessian Medical Education Program ... See MoreSee Less

Video

View on Facebook

Armenian American Health Professionals Organization

5 months ago

AAHPO congratulates Noubar Afeyan, Moderna Co-Founder & Chairman, entrepreneur and philanthropist, who recently received an honorary degree at McGill University on May 25th as part of the installation of a new university chancellor, John McCall MacBain. Afeyan, who received the degree of Doctor of Science, honoris causa (D.Sc.), is a graduate of McGill University as an undergraduate, with a doctoral degree from the Massachusetts Institute of Technology. @mcgillu @mitpics @mitstudents #pharma #biotech #doctorate #armenia #healthcare #philanthropy (credit: @armenianmirrorspectator ) ... See MoreSee Less

Photo

View on Facebook

Armenian American Health Professionals Organization

5 months ago

Landmark rectal cancer trial results: @memorialsloankettering Cancer Center made headlines — and history — as medical oncologists Andrea Cercek, MD, Section Head of Colorectal Cancer and Co-Director of the Center for Young Onset Colorectal and Gastrointestinal Cancer, and Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, shared the remarkable results of a clinical trial for rectal cancer at the annual meeting of the @ascocancer .In a small study of people with locally advanced disease, a single immunotherapy drug eliminated all evidence of cancer in every patient within six months. More than two years later, the group remains healthy. This is the first trial in cancer history in which every patient achieved complete remission, and the results may impact the standard of care for some types of rectal cancer. The study was published in The New England Journal of Medicine. @nejm #ASCO2022 #MMRd #immunotherapy #oncology #clinicalresearch ... See MoreSee Less

Photo

View on Facebook